STEMCELL-TECH
STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the opening of its new Canadian sales office at the MaRS Centre in downtown Toronto, Ontario.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231026694197/en/
STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the opening of its new Canadian sales office at the MaRS Centre, located in the heart of downtown Toronto’s Discovery District. (Photo: Business Wire)
“The opening of our new Toronto base marks a major milestone in STEMCELL’s 30-year history and is a testament to our growing presence in North America,” said Dr. Allen Eaves, President and CEO, STEMCELL. “This facility will enable us to strengthen ties in the Toronto area and better support the scientists in both academia and industry who are doing great work here.”
Located in the city’s Discovery District, the MaRS Centre is North America’s largest urban innovation hub. Consisting of over 1.5 million square feet, it hosts a curated roster of more than 120 tenants, including globally recognized research labs, tech corporates, capital providers, and many of Canada’s most promising health and life sciences startups. STEMCELL will take up occupancy at MaRS' West Tower, a LEED Gold building, at 661 University Avenue.
“As a company of Scientist Helping Scientists, STEMCELL is looking forward to being part of the MaRS community and collaborating with leading principal investigators to tackle some of the biggest challenges of our time,” said Dr. Eaves.
Headquartered in Vancouver, British Columbia, STEMCELL has a global presence, with offices in eight countries: Canada, United States, United Kingdom, France, Germany, China, South Korea, and Singapore. In total, STEMCELL has sales staff in 20 countries and distributors in 80 other countries. Of its 2400 global employees, 1800 are based in Canada.
STEMCELL’s connection with MaRS began when the company commissioned bronze portraits of Drs. James Till and Ernest McCulloch—considered the pioneers of stem cell research—by artist Ruth Abernethy. Unveiled in 2017, the sculpture was donated to MaRS by STEMCELL and today sits outside the MaRS Centre entrance. A sister sculpture can be found in front of Vancouver’s Science World near STEMCELL’s head office.
“As a PhD student, I was honored to study under Drs. Till and McCulloch, and so the opening of this office at MaRS close to the University of Toronto is especially meaningful for me,” said Dr. Eaves. “This is where it all began for stem cell research and where, in large part thanks to Drs. Till and McCulloch, my own career in this area of science started. It is important to me that STEMCELL continues to build on their legacy and make big contributions to the science, biotech, and innovation ecosystem here in Toronto and beyond.”
More information about the MaRS Centre can be found by visiting https://www.marsdd.com.
About STEMCELL Technologies
STEMCELL Technologies supports life sciences research with more than 2500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231026694197/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom